JP7426117B2 - 抗皮膚老化剤 - Google Patents
抗皮膚老化剤 Download PDFInfo
- Publication number
- JP7426117B2 JP7426117B2 JP2021188607A JP2021188607A JP7426117B2 JP 7426117 B2 JP7426117 B2 JP 7426117B2 JP 2021188607 A JP2021188607 A JP 2021188607A JP 2021188607 A JP2021188607 A JP 2021188607A JP 7426117 B2 JP7426117 B2 JP 7426117B2
- Authority
- JP
- Japan
- Prior art keywords
- sample
- skin
- extract
- cells
- mrna expression
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 230000009759 skin aging Effects 0.000 title description 13
- 239000000284 extract Substances 0.000 claims description 88
- 230000014509 gene expression Effects 0.000 claims description 85
- 108020004999 messenger RNA Proteins 0.000 claims description 75
- 108090000623 proteins and genes Proteins 0.000 claims description 42
- 244000207620 Euterpe oleracea Species 0.000 claims description 21
- 235000012601 Euterpe oleracea Nutrition 0.000 claims description 20
- 235000003650 acai Nutrition 0.000 claims description 18
- 230000007423 decrease Effects 0.000 claims description 17
- 230000006378 damage Effects 0.000 claims description 16
- 239000004480 active ingredient Substances 0.000 claims description 11
- 230000032683 aging Effects 0.000 claims description 11
- 108010082786 Interleukin-1alpha Proteins 0.000 claims description 9
- 102100033601 Collagen alpha-1(I) chain Human genes 0.000 claims description 7
- 102000004125 Interleukin-1alpha Human genes 0.000 claims description 7
- 235000013399 edible fruits Nutrition 0.000 claims description 6
- 108010029483 alpha 1 Chain Collagen Type I Proteins 0.000 claims description 4
- 101000945357 Homo sapiens Collagen alpha-1(I) chain Proteins 0.000 claims description 3
- 101000741967 Homo sapiens Presequence protease, mitochondrial Proteins 0.000 claims description 3
- 102100038632 Presequence protease, mitochondrial Human genes 0.000 claims description 3
- 239000011159 matrix material Substances 0.000 claims description 3
- 230000001629 suppression Effects 0.000 claims description 3
- 239000000523 sample Substances 0.000 description 139
- 210000004027 cell Anatomy 0.000 description 99
- 230000001737 promoting effect Effects 0.000 description 94
- 238000012360 testing method Methods 0.000 description 72
- 239000002609 medium Substances 0.000 description 71
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 70
- 238000004519 manufacturing process Methods 0.000 description 64
- 210000003491 skin Anatomy 0.000 description 62
- 230000003712 anti-aging effect Effects 0.000 description 46
- 230000000694 effects Effects 0.000 description 45
- 210000000434 stratum corneum Anatomy 0.000 description 38
- 239000003795 chemical substances by application Substances 0.000 description 37
- 108010024636 Glutathione Proteins 0.000 description 35
- 210000005175 epidermal keratinocyte Anatomy 0.000 description 35
- 229960003180 glutathione Drugs 0.000 description 35
- 235000018102 proteins Nutrition 0.000 description 30
- 102000004169 proteins and genes Human genes 0.000 description 30
- 230000037319 collagen production Effects 0.000 description 29
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 27
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 25
- 238000011282 treatment Methods 0.000 description 25
- 238000000605 extraction Methods 0.000 description 24
- 108010028309 kalinin Proteins 0.000 description 23
- 102000004669 Protein-Lysine 6-Oxidase Human genes 0.000 description 22
- 108010003894 Protein-Lysine 6-Oxidase Proteins 0.000 description 22
- 102100030944 Protein-glutamine gamma-glutamyltransferase K Human genes 0.000 description 22
- 108010058734 transglutaminase 1 Proteins 0.000 description 22
- 102100031455 NAD-dependent protein deacetylase sirtuin-1 Human genes 0.000 description 21
- 108010041191 Sirtuin 1 Proteins 0.000 description 21
- 230000006315 carbonylation Effects 0.000 description 21
- 238000005810 carbonylation reaction Methods 0.000 description 21
- 102000004363 Aquaporin 3 Human genes 0.000 description 20
- 108090000991 Aquaporin 3 Proteins 0.000 description 20
- 108700041153 Filaggrin Proteins Proteins 0.000 description 20
- 108010042086 Collagen Type IV Proteins 0.000 description 18
- 102000004266 Collagen Type IV Human genes 0.000 description 18
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 18
- 108010022452 Collagen Type I Proteins 0.000 description 17
- 102000012422 Collagen Type I Human genes 0.000 description 17
- 102000004162 Claudin-1 Human genes 0.000 description 16
- 108090000600 Claudin-1 Proteins 0.000 description 16
- 238000012258 culturing Methods 0.000 description 16
- 210000002615 epidermis Anatomy 0.000 description 15
- 102000008186 Collagen Human genes 0.000 description 14
- 108010035532 Collagen Proteins 0.000 description 14
- 230000004888 barrier function Effects 0.000 description 14
- 229920001436 collagen Polymers 0.000 description 14
- 201000010099 disease Diseases 0.000 description 14
- 239000000126 substance Substances 0.000 description 14
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 13
- 230000006870 function Effects 0.000 description 13
- 239000001301 oxygen Substances 0.000 description 13
- 229910052760 oxygen Inorganic materials 0.000 description 13
- 102000004142 Trypsin Human genes 0.000 description 12
- 108090000631 Trypsin Proteins 0.000 description 12
- 239000002904 solvent Substances 0.000 description 12
- 239000012588 trypsin Substances 0.000 description 12
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 11
- 230000009471 action Effects 0.000 description 11
- 238000012937 correction Methods 0.000 description 11
- 235000013305 food Nutrition 0.000 description 11
- 230000035755 proliferation Effects 0.000 description 11
- 102100031181 Glyceraldehyde-3-phosphate dehydrogenase Human genes 0.000 description 10
- 238000002835 absorbance Methods 0.000 description 10
- 210000002469 basement membrane Anatomy 0.000 description 10
- 239000003814 drug Substances 0.000 description 10
- 108020004445 glyceraldehyde-3-phosphate dehydrogenase Proteins 0.000 description 10
- 239000002994 raw material Substances 0.000 description 10
- 206010013786 Dry skin Diseases 0.000 description 9
- 108010076876 Keratins Proteins 0.000 description 9
- 102000011782 Keratins Human genes 0.000 description 9
- 230000002292 Radical scavenging effect Effects 0.000 description 9
- 238000006243 chemical reaction Methods 0.000 description 9
- 230000037336 dry skin Effects 0.000 description 9
- 239000000835 fiber Substances 0.000 description 9
- 238000000034 method Methods 0.000 description 9
- -1 peroxidized lipids Chemical class 0.000 description 9
- 238000003757 reverse transcription PCR Methods 0.000 description 9
- 229940000957 acai extract Drugs 0.000 description 8
- 235000015800 acai extract Nutrition 0.000 description 8
- 239000000203 mixture Substances 0.000 description 8
- 208000024891 symptom Diseases 0.000 description 8
- 206010012438 Dermatitis atopic Diseases 0.000 description 7
- 102100028314 Filaggrin Human genes 0.000 description 7
- 101710088660 Filaggrin Proteins 0.000 description 7
- 201000008937 atopic dermatitis Diseases 0.000 description 7
- 230000015572 biosynthetic process Effects 0.000 description 7
- 239000007789 gas Substances 0.000 description 7
- 239000001963 growth medium Substances 0.000 description 7
- 230000036542 oxidative stress Effects 0.000 description 7
- 238000002360 preparation method Methods 0.000 description 7
- 238000002965 ELISA Methods 0.000 description 6
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 6
- OUUQCZGPVNCOIJ-UHFFFAOYSA-M Superoxide Chemical compound [O-][O] OUUQCZGPVNCOIJ-UHFFFAOYSA-M 0.000 description 6
- 210000002950 fibroblast Anatomy 0.000 description 6
- 230000002265 prevention Effects 0.000 description 6
- 210000001626 skin fibroblast Anatomy 0.000 description 6
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 5
- 239000000872 buffer Substances 0.000 description 5
- 239000002537 cosmetic Substances 0.000 description 5
- 229940079593 drug Drugs 0.000 description 5
- 210000004177 elastic tissue Anatomy 0.000 description 5
- 230000002401 inhibitory effect Effects 0.000 description 5
- 238000005259 measurement Methods 0.000 description 5
- 238000002156 mixing Methods 0.000 description 5
- 239000002953 phosphate buffered saline Substances 0.000 description 5
- 238000003753 real-time PCR Methods 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- 230000037303 wrinkles Effects 0.000 description 5
- 102000002029 Claudin Human genes 0.000 description 4
- 108050009302 Claudin Proteins 0.000 description 4
- 201000004624 Dermatitis Diseases 0.000 description 4
- 102000004190 Enzymes Human genes 0.000 description 4
- 108090000790 Enzymes Proteins 0.000 description 4
- 108010085895 Laminin Proteins 0.000 description 4
- 206010051246 Photodermatosis Diseases 0.000 description 4
- 208000027418 Wounds and injury Diseases 0.000 description 4
- 235000001014 amino acid Nutrition 0.000 description 4
- 150000001413 amino acids Chemical class 0.000 description 4
- 210000000736 corneocyte Anatomy 0.000 description 4
- 230000003247 decreasing effect Effects 0.000 description 4
- 230000007812 deficiency Effects 0.000 description 4
- 210000004207 dermis Anatomy 0.000 description 4
- 238000001514 detection method Methods 0.000 description 4
- 206010012601 diabetes mellitus Diseases 0.000 description 4
- 210000002744 extracellular matrix Anatomy 0.000 description 4
- 230000035876 healing Effects 0.000 description 4
- 230000036541 health Effects 0.000 description 4
- 238000010438 heat treatment Methods 0.000 description 4
- 239000003112 inhibitor Substances 0.000 description 4
- 210000002510 keratinocyte Anatomy 0.000 description 4
- 150000002632 lipids Chemical class 0.000 description 4
- 239000006210 lotion Substances 0.000 description 4
- VMGAPWLDMVPYIA-HIDZBRGKSA-N n'-amino-n-iminomethanimidamide Chemical compound N\N=C\N=N VMGAPWLDMVPYIA-HIDZBRGKSA-N 0.000 description 4
- 229930014626 natural product Natural products 0.000 description 4
- 230000008845 photoaging Effects 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- BOLDJAUMGUJJKM-LSDHHAIUSA-N renifolin D Natural products CC(=C)[C@@H]1Cc2c(O)c(O)ccc2[C@H]1CC(=O)c3ccc(O)cc3O BOLDJAUMGUJJKM-LSDHHAIUSA-N 0.000 description 4
- 210000001519 tissue Anatomy 0.000 description 4
- ZWEHNKRNPOVVGH-UHFFFAOYSA-N 2-Butanone Chemical compound CCC(C)=O ZWEHNKRNPOVVGH-UHFFFAOYSA-N 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- 102000010637 Aquaporins Human genes 0.000 description 3
- 208000035473 Communicable disease Diseases 0.000 description 3
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 3
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 3
- 241000282412 Homo Species 0.000 description 3
- 239000007987 MES buffer Substances 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 208000001132 Osteoporosis Diseases 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 206010052428 Wound Diseases 0.000 description 3
- 239000003963 antioxidant agent Substances 0.000 description 3
- 230000003078 antioxidant effect Effects 0.000 description 3
- 108091006003 carbonylated proteins Proteins 0.000 description 3
- 210000000170 cell membrane Anatomy 0.000 description 3
- 239000000470 constituent Substances 0.000 description 3
- 238000004132 cross linking Methods 0.000 description 3
- 238000001035 drying Methods 0.000 description 3
- 210000001339 epidermal cell Anatomy 0.000 description 3
- 239000003205 fragrance Substances 0.000 description 3
- 239000008187 granular material Substances 0.000 description 3
- 206010021198 ichthyosis Diseases 0.000 description 3
- 230000003020 moisturizing effect Effects 0.000 description 3
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 3
- 230000003647 oxidation Effects 0.000 description 3
- 238000007254 oxidation reaction Methods 0.000 description 3
- 239000008363 phosphate buffer Substances 0.000 description 3
- 230000019612 pigmentation Effects 0.000 description 3
- 239000002798 polar solvent Substances 0.000 description 3
- 239000012488 sample solution Substances 0.000 description 3
- 150000005846 sugar alcohols Polymers 0.000 description 3
- 230000029663 wound healing Effects 0.000 description 3
- 230000037373 wrinkle formation Effects 0.000 description 3
- DNIAPMSPPWPWGF-GSVOUGTGSA-N (R)-(-)-Propylene glycol Chemical compound C[C@@H](O)CO DNIAPMSPPWPWGF-GSVOUGTGSA-N 0.000 description 2
- KIUMMUBSPKGMOY-UHFFFAOYSA-N 3,3'-Dithiobis(6-nitrobenzoic acid) Chemical compound C1=C([N+]([O-])=O)C(C(=O)O)=CC(SSC=2C=C(C(=CC=2)[N+]([O-])=O)C(O)=O)=C1 KIUMMUBSPKGMOY-UHFFFAOYSA-N 0.000 description 2
- 108010063290 Aquaporins Proteins 0.000 description 2
- 206010003210 Arteriosclerosis Diseases 0.000 description 2
- 208000012657 Atopic disease Diseases 0.000 description 2
- 240000006063 Averrhoa carambola Species 0.000 description 2
- 235000010082 Averrhoa carambola Nutrition 0.000 description 2
- 208000009137 Behcet syndrome Diseases 0.000 description 2
- 101150008656 COL1A1 gene Proteins 0.000 description 2
- 208000024172 Cardiovascular disease Diseases 0.000 description 2
- 108010014258 Elastin Proteins 0.000 description 2
- 102000016942 Elastin Human genes 0.000 description 2
- 206010014989 Epidermolysis bullosa Diseases 0.000 description 2
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 2
- 241001677214 Euterpe precatoria Species 0.000 description 2
- 108010053070 Glutathione Disulfide Proteins 0.000 description 2
- 108010063907 Glutathione Reductase Proteins 0.000 description 2
- 102100036442 Glutathione reductase, mitochondrial Human genes 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 239000012981 Hank's balanced salt solution Substances 0.000 description 2
- 206010020751 Hypersensitivity Diseases 0.000 description 2
- 208000012902 Nervous system disease Diseases 0.000 description 2
- 208000003251 Pruritus Diseases 0.000 description 2
- 201000004681 Psoriasis Diseases 0.000 description 2
- 244000141804 Theobroma grandiflorum Species 0.000 description 2
- 235000002424 Theobroma grandiflorum Nutrition 0.000 description 2
- 208000026062 Tissue disease Diseases 0.000 description 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
- XJLXINKUBYWONI-DQQFMEOOSA-N [[(2r,3r,4r,5r)-5-(6-aminopurin-9-yl)-3-hydroxy-4-phosphonooxyoxolan-2-yl]methoxy-hydroxyphosphoryl] [(2s,3r,4s,5s)-5-(3-carbamoylpyridin-1-ium-1-yl)-3,4-dihydroxyoxolan-2-yl]methyl phosphate Chemical compound NC(=O)C1=CC=C[N+]([C@@H]2[C@H]([C@@H](O)[C@H](COP([O-])(=O)OP(O)(=O)OC[C@@H]3[C@H]([C@@H](OP(O)(O)=O)[C@@H](O3)N3C4=NC=NC(N)=C4N=C3)O)O2)O)=C1 XJLXINKUBYWONI-DQQFMEOOSA-N 0.000 description 2
- 125000003172 aldehyde group Chemical group 0.000 description 2
- 230000007815 allergy Effects 0.000 description 2
- 208000011775 arteriosclerosis disease Diseases 0.000 description 2
- 208000006673 asthma Diseases 0.000 description 2
- 208000010668 atopic eczema Diseases 0.000 description 2
- 239000012752 auxiliary agent Substances 0.000 description 2
- 238000011088 calibration curve Methods 0.000 description 2
- 125000004432 carbon atom Chemical group C* 0.000 description 2
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 2
- 230000032677 cell aging Effects 0.000 description 2
- 230000030833 cell death Effects 0.000 description 2
- 230000009087 cell motility Effects 0.000 description 2
- 206010008118 cerebral infarction Diseases 0.000 description 2
- 239000012141 concentrate Substances 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 2
- 230000002950 deficient Effects 0.000 description 2
- 238000005238 degreasing Methods 0.000 description 2
- RXKJFZQQPQGTFL-UHFFFAOYSA-N dihydroxyacetone Chemical compound OCC(=O)CO RXKJFZQQPQGTFL-UHFFFAOYSA-N 0.000 description 2
- 230000001819 effect on gene Effects 0.000 description 2
- 230000007613 environmental effect Effects 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- YPZRWBKMTBYPTK-BJDJZHNGSA-N glutathione disulfide Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@H](C(=O)NCC(O)=O)CSSC[C@@H](C(=O)NCC(O)=O)NC(=O)CC[C@H](N)C(O)=O YPZRWBKMTBYPTK-BJDJZHNGSA-N 0.000 description 2
- 235000011187 glycerol Nutrition 0.000 description 2
- 229910001385 heavy metal Inorganic materials 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 208000027866 inflammatory disease Diseases 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 238000005342 ion exchange Methods 0.000 description 2
- 230000007803 itching Effects 0.000 description 2
- 230000003780 keratinization Effects 0.000 description 2
- 108010075526 keratohyalin Proteins 0.000 description 2
- 210000003041 ligament Anatomy 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 230000014759 maintenance of location Effects 0.000 description 2
- 230000007102 metabolic function Effects 0.000 description 2
- 239000011259 mixed solution Substances 0.000 description 2
- 208000031225 myocardial ischemia Diseases 0.000 description 2
- 229930027945 nicotinamide-adenine dinucleotide Natural products 0.000 description 2
- 239000003921 oil Substances 0.000 description 2
- 239000002674 ointment Substances 0.000 description 2
- 239000003960 organic solvent Substances 0.000 description 2
- YPZRWBKMTBYPTK-UHFFFAOYSA-N oxidized gamma-L-glutamyl-L-cysteinylglycine Natural products OC(=O)C(N)CCC(=O)NC(C(=O)NCC(O)=O)CSSCC(C(=O)NCC(O)=O)NC(=O)CCC(N)C(O)=O YPZRWBKMTBYPTK-UHFFFAOYSA-N 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 2
- 239000012264 purified product Substances 0.000 description 2
- 239000002516 radical scavenger Substances 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 206010039073 rheumatoid arthritis Diseases 0.000 description 2
- 239000002453 shampoo Substances 0.000 description 2
- 210000004927 skin cell Anatomy 0.000 description 2
- 210000000498 stratum granulosum Anatomy 0.000 description 2
- 210000002435 tendon Anatomy 0.000 description 2
- 210000001578 tight junction Anatomy 0.000 description 2
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 1
- HVCNXQOWACZAFN-UHFFFAOYSA-N 4-ethylmorpholine Chemical compound CCN1CCOCC1 HVCNXQOWACZAFN-UHFFFAOYSA-N 0.000 description 1
- MEUCHQDLZYLNQY-UHFFFAOYSA-N 5-(aminocarbamothioylamino)-2-(3-hydroxy-6-oxoxanthen-9-yl)benzoic acid Chemical compound OC(=O)C1=CC(NC(=S)NN)=CC=C1C1=C2C=CC(=O)C=C2OC2=CC(O)=CC=C21 MEUCHQDLZYLNQY-UHFFFAOYSA-N 0.000 description 1
- 208000024827 Alzheimer disease Diseases 0.000 description 1
- 102100023987 Aquaporin-12A Human genes 0.000 description 1
- 241000233788 Arecaceae Species 0.000 description 1
- 244000003416 Asparagus officinalis Species 0.000 description 1
- 235000005340 Asparagus officinalis Nutrition 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 201000006474 Brain Ischemia Diseases 0.000 description 1
- YDNKGFDKKRUKPY-JHOUSYSJSA-N C16 ceramide Natural products CCCCCCCCCCCCCCCC(=O)N[C@@H](CO)[C@H](O)C=CCCCCCCCCCCCCC YDNKGFDKKRUKPY-JHOUSYSJSA-N 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 208000002177 Cataract Diseases 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 206010008120 Cerebral ischaemia Diseases 0.000 description 1
- 208000032170 Congenital Abnormalities Diseases 0.000 description 1
- 206010010356 Congenital anomaly Diseases 0.000 description 1
- 235000016071 Cordyline australis Nutrition 0.000 description 1
- 241000699800 Cricetinae Species 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 241000202707 Euterpe Species 0.000 description 1
- 206010064503 Excessive skin Diseases 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- BBBXWRGITSUJPB-YUMQZZPRSA-N Glu-Lys Chemical compound NCCCC[C@@H](C(O)=O)NC(=O)[C@@H](N)CCC(O)=O BBBXWRGITSUJPB-YUMQZZPRSA-N 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 101000757607 Homo sapiens Aquaporin-12A Proteins 0.000 description 1
- 208000023105 Huntington disease Diseases 0.000 description 1
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 1
- 208000026350 Inborn Genetic disease Diseases 0.000 description 1
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- 102100023487 Lens fiber major intrinsic protein Human genes 0.000 description 1
- FURUXTVZLHCCNA-UHFFFAOYSA-N Liquiritigenin Natural products C1=CC(O)=CC=C1C1OC2=CC(O)=CC=C2C(=O)C1 FURUXTVZLHCCNA-UHFFFAOYSA-N 0.000 description 1
- 206010067125 Liver injury Diseases 0.000 description 1
- 208000019693 Lung disease Diseases 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 238000000134 MTT assay Methods 0.000 description 1
- 231100000002 MTT assay Toxicity 0.000 description 1
- 241000219071 Malvaceae Species 0.000 description 1
- 244000062730 Melissa officinalis Species 0.000 description 1
- 235000010654 Melissa officinalis Nutrition 0.000 description 1
- 108010052285 Membrane Proteins Proteins 0.000 description 1
- 102000018697 Membrane Proteins Human genes 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- CRJGESKKUOMBCT-VQTJNVASSA-N N-acetylsphinganine Chemical compound CCCCCCCCCCCCCCC[C@@H](O)[C@H](CO)NC(C)=O CRJGESKKUOMBCT-VQTJNVASSA-N 0.000 description 1
- 101710188518 NAD-dependent protein deacetylase Proteins 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 244000061176 Nicotiana tabacum Species 0.000 description 1
- 235000002637 Nicotiana tabacum Nutrition 0.000 description 1
- 208000018737 Parkinson disease Diseases 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 235000008947 Roystonea oleracea Nutrition 0.000 description 1
- 235000001601 Sabal palmetto Nutrition 0.000 description 1
- 102000011990 Sirtuin Human genes 0.000 description 1
- 108050002485 Sirtuin Proteins 0.000 description 1
- 206010040954 Skin wrinkling Diseases 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 244000269722 Thea sinensis Species 0.000 description 1
- 244000299461 Theobroma cacao Species 0.000 description 1
- 235000005764 Theobroma cacao ssp. cacao Nutrition 0.000 description 1
- 235000005767 Theobroma cacao ssp. sphaerocarpum Nutrition 0.000 description 1
- 108010077465 Tropocollagen Proteins 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 239000000809 air pollutant Substances 0.000 description 1
- 231100001243 air pollutant Toxicity 0.000 description 1
- 150000001299 aldehydes Chemical class 0.000 description 1
- 239000013566 allergen Substances 0.000 description 1
- 125000000539 amino acid group Chemical group 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 108010018755 aquaporin 0 Proteins 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 125000004429 atom Chemical group 0.000 description 1
- 230000003796 beauty Effects 0.000 description 1
- 235000013361 beverage Nutrition 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 230000003139 buffering effect Effects 0.000 description 1
- 235000001046 cacaotero Nutrition 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 230000021164 cell adhesion Effects 0.000 description 1
- 230000005779 cell damage Effects 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 208000037887 cell injury Diseases 0.000 description 1
- 210000003855 cell nucleus Anatomy 0.000 description 1
- 108091092356 cellular DNA Proteins 0.000 description 1
- ZVEQCJWYRWKARO-UHFFFAOYSA-N ceramide Natural products CCCCCCCCCCCCCCC(O)C(=O)NC(CO)C(O)C=CCCC=C(C)CCCCCCCCC ZVEQCJWYRWKARO-UHFFFAOYSA-N 0.000 description 1
- 229940106189 ceramide Drugs 0.000 description 1
- 208000026106 cerebrovascular disease Diseases 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 235000019504 cigarettes Nutrition 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 230000016396 cytokine production Effects 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 238000000151 deposition Methods 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 230000035622 drinking Effects 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 229920002549 elastin Polymers 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 230000037149 energy metabolism Effects 0.000 description 1
- 210000000981 epithelium Anatomy 0.000 description 1
- YSMODUONRAFBET-UHNVWZDZSA-N erythro-5-hydroxy-L-lysine Chemical group NC[C@H](O)CC[C@H](N)C(O)=O YSMODUONRAFBET-UHNVWZDZSA-N 0.000 description 1
- 239000001403 euterpe oleracea fruit extract Substances 0.000 description 1
- 238000004299 exfoliation Methods 0.000 description 1
- 210000001723 extracellular space Anatomy 0.000 description 1
- 239000003925 fat Substances 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000013505 freshwater Substances 0.000 description 1
- 230000008717 functional decline Effects 0.000 description 1
- 235000013376 functional food Nutrition 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 208000016361 genetic disease Diseases 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- 235000013402 health food Nutrition 0.000 description 1
- 231100000234 hepatic damage Toxicity 0.000 description 1
- 230000013632 homeostatic process Effects 0.000 description 1
- 229920002674 hyaluronan Polymers 0.000 description 1
- 229960003160 hyaluronic acid Drugs 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
- TUJKJAMUKRIRHC-UHFFFAOYSA-N hydroxyl Chemical compound [OH] TUJKJAMUKRIRHC-UHFFFAOYSA-N 0.000 description 1
- 201000002597 ichthyosis vulgaris Diseases 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 230000005732 intercellular adhesion Effects 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- 230000000622 irritating effect Effects 0.000 description 1
- JBQATDIMBVLPRB-UHFFFAOYSA-N isoliquiritigenin Natural products OC1=CC(O)=CC=C1C1OC2=CC(O)=CC=C2C(=O)C1 JBQATDIMBVLPRB-UHFFFAOYSA-N 0.000 description 1
- 208000008106 junctional epidermolysis bullosa Diseases 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 208000017169 kidney disease Diseases 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 108010057670 laminin 1 Proteins 0.000 description 1
- 229940069445 licorice extract Drugs 0.000 description 1
- 239000000865 liniment Substances 0.000 description 1
- FURUXTVZLHCCNA-AWEZNQCLSA-N liquiritigenin Chemical compound C1=CC(O)=CC=C1[C@H]1OC2=CC(O)=CC=C2C(=O)C1 FURUXTVZLHCCNA-AWEZNQCLSA-N 0.000 description 1
- 230000008818 liver damage Effects 0.000 description 1
- 208000019423 liver disease Diseases 0.000 description 1
- 230000033001 locomotion Effects 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 239000002932 luster Substances 0.000 description 1
- 125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 1
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 1
- 235000019341 magnesium sulphate Nutrition 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 210000004379 membrane Anatomy 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 210000001724 microfibril Anatomy 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 230000002107 myocardial effect Effects 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- 230000004770 neurodegeneration Effects 0.000 description 1
- 208000015122 neurodegenerative disease Diseases 0.000 description 1
- 230000000324 neuroprotective effect Effects 0.000 description 1
- VVGIYYKRAMHVLU-UHFFFAOYSA-N newbouldiamide Natural products CCCCCCCCCCCCCCCCCCCC(O)C(O)C(O)C(CO)NC(=O)CCCCCCCCCCCCCCCCC VVGIYYKRAMHVLU-UHFFFAOYSA-N 0.000 description 1
- 239000012454 non-polar solvent Substances 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 210000004798 organs belonging to the digestive system Anatomy 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 230000000149 penetrating effect Effects 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 239000000419 plant extract Substances 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 230000006318 protein oxidation Effects 0.000 description 1
- 238000010298 pulverizing process Methods 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 239000008213 purified water Substances 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 239000003642 reactive oxygen metabolite Substances 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 230000001172 regenerating effect Effects 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- 210000002374 sebum Anatomy 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 230000037380 skin damage Effects 0.000 description 1
- 208000017520 skin disease Diseases 0.000 description 1
- 230000037394 skin elasticity Effects 0.000 description 1
- 230000004215 skin function Effects 0.000 description 1
- 230000005808 skin problem Effects 0.000 description 1
- 230000036558 skin tension Effects 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 239000000779 smoke Substances 0.000 description 1
- 230000000391 smoking effect Effects 0.000 description 1
- 239000000344 soap Substances 0.000 description 1
- GSZUGBAEBARHAW-UHFFFAOYSA-N sophoraflavone B Natural products OC1C(O)C(O)C(CO)OC1OC1=CC=C(C=2OC3=CC(O)=CC=C3C(=O)C=2)C=C1 GSZUGBAEBARHAW-UHFFFAOYSA-N 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 210000000438 stratum basale Anatomy 0.000 description 1
- 210000000437 stratum spinosum Anatomy 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 239000008399 tap water Substances 0.000 description 1
- 235000020679 tap water Nutrition 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 235000015961 tonic Nutrition 0.000 description 1
- 230000001256 tonic effect Effects 0.000 description 1
- 229960000716 tonics Drugs 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 108700012359 toxins Proteins 0.000 description 1
- 239000002349 well water Substances 0.000 description 1
- 235000020681 well water Nutrition 0.000 description 1
Landscapes
- Cosmetics (AREA)
- Medicines Containing Plant Substances (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
Description
本実施形態の抗老化剤は、クプアスからの抽出物および/またはアサイーからの抽出物を有効成分とするものである。
クプアス抽出物(試料1)について、以下のようにしてラジカル消去作用を試験した。
式中の各項はそれぞれ以下を表す。
A:試料無添加での波長520nmにおける吸光度
B:被験試料添加での波長520nmにおける吸光度
C:被験試料添加直後(ブランク)の波長520nmにおける吸光度
結果を表1に示す。
クプアス抽出物(試料1)について、以下のようにしてI型コラーゲン産生促進作用を試験した。
式中の各項はそれぞれ以下を表す。
A:被験試料添加でのI型コラーゲン量
B:試料無添加でのI型コラーゲン量
結果を表2に示す。
クプアス抽出物(試料1)について、以下のようにしてIV型コラーゲン産生促進作用を試験した。
式中の各項はそれぞれ以下を表す。
A:被験試料添加でのIV型コラーゲン量
B:試料無添加でのIV型コラーゲン量
結果を表3に示す。
クプアス抽出物(試料1)について、以下のようにしてラミニン5産生促進作用を試験した。
式中の各項はそれぞれ以下を表す。
A:被験試料添加でのラミニン5量
B:試料無添加でのラミニン5量
結果を表4に示す。
クプアス抽出物(試料1)について、以下のようにして表皮角化細胞増殖促進作用を試験した。
式中の各項はそれぞれ以下を表す。
A:被験試料添加でのブルーホルマザン生成量
B:試料無添加でのブルーホルマザン生成量
結果を表5に示す。
クプアス抽出物(試料1)について、以下のようにして、線維芽細胞におけるグルタチオン産生促進作用を試験した。
式中の各項はそれぞれ以下を表す。
A:試料無添加における総タンパク量当たりのグルタチオン量
B:被験試料添加における総タンパク量当たりのグルタチオン量
結果を表6に示す。
クプアス抽出物(試料1)について、以下のようにして、表皮角化細胞におけるグルタチオン産生促進作用を試験した。
式中の各項はそれぞれ以下を表す。
A:試料無添加における総タンパク量当たりのグルタチオン量
B:被験試料添加における総タンパク量当たりのグルタチオン量
結果を表7に示す。
クプアス抽出物(試料1)について、以下のようにしてトランスグルタミナーゼ-1産生促進作用を試験した。
式中の各項はそれぞれ以下を表す。
A:被験試料添加でのトランスグルタミナーゼ-1量
B:試料無添加でのトランスグルタミナーゼ-1量
結果を表8に示す。
クプアス抽出物(試料1)について、以下のようにしてプロフィラグリンmRNA発現促進作用を試験した。
式中の各項はそれぞれ以下を表す。
A:被験試料添加での補正値
B:試料無添加での補正値
結果を表9に示す。
クプアス抽出物(試料1)について、以下のようにしてAQP3 mRNA発現促進作用を試験した。
式中の各項はそれぞれ以下を表す。
A:被験試料添加での補正値
B:試料無添加での補正値
結果を表10に示す。
クプアス抽出物(試料1)について、以下のようにしてクローディン-1産生促進作用を試験した。
式中の各項はそれぞれ以下を表す。
A:被験試料添加でのクローディン-1量
B:試料無添加でのクローディン-1量
結果を表11に示す。
クプアス抽出物(試料1)について、以下のようにしてSIRT1 mRNA発現促進作用を試験した。
式中の各項はそれぞれ以下を表す。
A:被験試料添加での補正値
B:試料無添加での補正値
結果を表12に示す。
クプアス抽出物(試料1)について、以下のようにしてLOX mRNA発現促進作用を試験した。
式中の各項はそれぞれ以下を表す。
A:被験試料添加での補正値
B:試料無添加での補正値
結果を表13に示す。
クプアス抽出物(試料1)について、以下のようにして、排気ガスによる角層タンパク質カルボニル化の抑制作用を試験した。
式中の各項はそれぞれ以下を表す。
A:排気ガス処理・被験試料添加でのカルボニル化レベル
B:排気ガス処理・試料無添加(コントロール)でのカルボニル化レベル
C:排気ガス非処理・試料無添加(ブランク)でのカルボニル化レベル
結果を表14に示す。
アサイー抽出物(試料2)について、以下のようにして、紫外線(UVA)による遺伝子発現変動の抑制作用を試験した。
式中の各項はそれぞれ以下を表す。
A:紫外線非照射・試料無添加での補正値
B:紫外線照射・試料無添加(コントロール)での補正値
C:紫外線照射・被験試料添加での補正値
結果を表15に示す。
Claims (2)
- アサイーの果実からの抽出物を有効成分とする抗皮膚老化剤であって、
紫外線ダメージ抑制用途に用いられることを特徴とする抗皮膚老化剤。 - 前記紫外線ダメージ抑制用途が、
MMP-1(Matrix Metalloprotease-1)遺伝子のUVA照射によるmRNA発現上昇の抑制用途、IL-1α(Interleukin-1α)遺伝子のUVA照射によるmRNA発現上昇の抑制用途、およびCOL1A1(Collagen,TypeI,α1)遺伝子のUVA照射によるmRNA発現低下の抑制用途からなる群より選択される1または2以上の用途である
ことを特徴とする請求項1に記載の抗皮膚老化剤。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2021188607A JP7426117B2 (ja) | 2017-03-10 | 2021-11-19 | 抗皮膚老化剤 |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2017046799A JP6986251B2 (ja) | 2017-03-10 | 2017-03-10 | 抗老化剤 |
JP2021188607A JP7426117B2 (ja) | 2017-03-10 | 2021-11-19 | 抗皮膚老化剤 |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2017046799A Division JP6986251B2 (ja) | 2017-03-10 | 2017-03-10 | 抗老化剤 |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2022010412A JP2022010412A (ja) | 2022-01-14 |
JP7426117B2 true JP7426117B2 (ja) | 2024-02-01 |
Family
ID=63681293
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2017046799A Active JP6986251B2 (ja) | 2017-03-10 | 2017-03-10 | 抗老化剤 |
JP2021188607A Active JP7426117B2 (ja) | 2017-03-10 | 2021-11-19 | 抗皮膚老化剤 |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2017046799A Active JP6986251B2 (ja) | 2017-03-10 | 2017-03-10 | 抗老化剤 |
Country Status (1)
Country | Link |
---|---|
JP (2) | JP6986251B2 (ja) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP7301347B2 (ja) * | 2019-05-22 | 2023-07-03 | 株式会社ブルーム・クラシック | サーチュイン1活性化剤及びサーチュイン1活性化用皮膚化粧料 |
JP7455350B2 (ja) | 2019-10-17 | 2024-03-26 | 丸善製薬株式会社 | 大気汚染物質によるダメージ抑制剤、化粧料及び飲食品 |
KR102470948B1 (ko) * | 2019-11-27 | 2022-11-28 | (주)네오팜 | 강화된 액정에멀젼의 제조방법 |
CN116076711A (zh) * | 2021-11-05 | 2023-05-09 | 百岳特生物技术(上海)有限公司 | 益生质组合物及其用途 |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20070166275A1 (en) | 2006-01-19 | 2007-07-19 | Mary Kay Inc. | Compositions comprising kakadu plum extract or acai berry extract |
JP2009256326A (ja) | 2008-03-21 | 2009-11-05 | Kose Corp | 美白剤、及び皮膚外用剤 |
JP2011016727A (ja) | 2009-07-07 | 2011-01-27 | Oriza Yuka Kk | メラニン生成抑制剤 |
US20130156711A1 (en) | 2011-12-07 | 2013-06-20 | Mary Kay Inc. | Topical skin care formulation |
JP2015156812A (ja) | 2014-02-21 | 2015-09-03 | カルピス株式会社 | アサイー入り飲料 |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2013095667A (ja) * | 2011-10-28 | 2013-05-20 | Ichimaru Pharcos Co Ltd | アクアポリン産生増強製剤 |
-
2017
- 2017-03-10 JP JP2017046799A patent/JP6986251B2/ja active Active
-
2021
- 2021-11-19 JP JP2021188607A patent/JP7426117B2/ja active Active
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20070166275A1 (en) | 2006-01-19 | 2007-07-19 | Mary Kay Inc. | Compositions comprising kakadu plum extract or acai berry extract |
JP2009256326A (ja) | 2008-03-21 | 2009-11-05 | Kose Corp | 美白剤、及び皮膚外用剤 |
JP2011016727A (ja) | 2009-07-07 | 2011-01-27 | Oriza Yuka Kk | メラニン生成抑制剤 |
US20130156711A1 (en) | 2011-12-07 | 2013-06-20 | Mary Kay Inc. | Topical skin care formulation |
JP2015156812A (ja) | 2014-02-21 | 2015-09-03 | カルピス株式会社 | アサイー入り飲料 |
Also Published As
Publication number | Publication date |
---|---|
JP6986251B2 (ja) | 2021-12-22 |
JP2018150262A (ja) | 2018-09-27 |
JP2022010412A (ja) | 2022-01-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP7426117B2 (ja) | 抗皮膚老化剤 | |
JP7184397B2 (ja) | 皮膚化粧料、頭髪化粧料および飲食品 | |
JP5937965B2 (ja) | モリンガ種の完全な種子の抽出物並びに化粧品組成物及び/又は皮膚科学的組成物におけるその使用 | |
JP6788966B2 (ja) | 化粧料 | |
EP2953611B1 (fr) | Utilisation d'une composition comprenant un perséose d'avocat dans la protection des cellules souches épidermiques | |
JP5889546B2 (ja) | ヘキソサミニダーゼ遊離抑制剤、幹細胞増殖因子mRNA発現上昇抑制剤、過酸化水素細胞障害の予防・改善剤及びグルタチオン産生促進剤 | |
JP2009191039A (ja) | ヒアルロン酸合成酵素3mRNA発現促進剤、アクアポリン3mRNA発現促進剤、セリンパルミトイルトランスフェラーゼmRNA発現促進剤及びラミニン5産生促進剤 | |
EP2763652B1 (fr) | Utilisation de glucanes obtenus a partir de prunus persica comme agent cosmetique anti-age | |
JP5761888B2 (ja) | 抗老化剤及び皮膚化粧料 | |
JP2012162487A (ja) | 美白剤、抗老化剤及び皮膚化粧料 | |
JP7082827B2 (ja) | 化粧料 | |
JP2012041276A (ja) | タンパク質のカルボニル化抑制剤及び肌の透明感向上剤 | |
FR2928549A1 (fr) | Utilisation d'un extrait de l'orchidee brassocattleya marcella koss en tant qu'actif pour prevenir ou retarder l'apparition des signes du vieillissement cutane | |
JP2012219031A (ja) | ラミニン5産生促進剤、インテグリンα6β4産生促進剤、皮膚基底膜正常化剤、皮膚損傷回復促進剤及びアクアポリン3mRNA発現促進剤 | |
KR101997231B1 (ko) | 효소반응을 이용하여 제조된 꿀 추출물을 유효성분으로 함유하는 화장료 조성물 | |
WO2020203933A1 (ja) | 抗老化剤、抗酸化剤、抗炎症剤、及び美白剤、並びに、化粧料 | |
FR3049461A1 (fr) | Utilisation d'un extrait vegetal du fruit de pouteria lucuma dans une composition costique | |
JP2021127322A (ja) | ヒアルロン酸合成酵素3(HAS3)mRNA発現促進剤、セリンパルミトイルトランスフェラーゼ(SPT)mRNA発現促進剤、アクアポリン3(AQP3)mRNA発現促進剤、クローディン−1 mRNA発現促進剤、クローディン−4 mRNA発現促進剤およびオクルディン mRNA発現促進剤 | |
JP5566597B2 (ja) | I型コラーゲン産生促進剤、アデノシン三リン酸産生促進剤、フィラグリン産生促進剤、メラニン産生抑制剤、塩基性線維芽細胞増殖因子(bFGF)mRNA発現抑制剤、及び肌の透明感向上剤 | |
JP7215761B2 (ja) | 経口組成物、皮膚化粧料および頭髪化粧料 | |
WO2019077268A1 (fr) | Composition cosmétique de prévention active des signes de l'âge | |
JP7253283B2 (ja) | 化粧料および飲食品組成物 | |
JP7351541B2 (ja) | 皮膚化粧料、頭髪化粧料および飲食品 | |
CH706016A2 (de) | Auf Stammzellen der Epidermis und Dermis und auf deren Mikro-Umgebung wirkende kosmetische Zusammensetzung. | |
JP7411196B2 (ja) | Xvii型コラーゲン維持強化剤 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20211216 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20221115 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20221223 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20230310 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20230704 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20230904 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20231102 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20231226 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20240115 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 7426117 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |